Merck Wins Chance for Royalties on Gilead’s Hepatitis C Cure

  • Merck seeks royalty saying it paved way for liver remedy
  • Gilead dominates market with $20 billion U.S. sales since 2013

Merck & Co. won a sweeping jury verdict that allows it to seek royalties from Gilead Sciences Inc. for the drugs that have dominated the hepatitis C market with $20 billion in U.S. sales since 2013.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.